Sinovac Biotech, Ltd (SVA) Total Assets by Year
Sinovac Biotech, Ltd closed fiscal year 2025 with $8.5B in total assets, $4.1B in total liabilities and $4.4B in shareholder equity. This represents a decrease of 30.8% from the prior fiscal year. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Sinovac Biotech, Ltd has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
SVA Balance Sheet by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K | FY1110-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $8.5B-30.8% | $12.3B-9.4% | $13.6B-3.0% | $14.0B-16.3% | $16.8B+781.4% | $1.9B+320.4% | $452.3M+22.3% | $369.8M+23.6% | $299.2M+41.6% | $211.4M+4.2% | $202.9M-14.9% | $238.5M-0.9% | $240.7M+15.3% | $208.8M-3.3% | $215.9M |
| Total Liabilities | $4.1B+100.7% | $2.0B-61.4% | $5.3B-4.4% | $5.5B-28.6% | $7.8B+893.8% | $781.2M+680.4% | $100.1M+28.6% | $77.9M-36.2% | $122.1M+49.4% | $81.7M+23.0% | $66.4M-31.4% | $96.8M-0.3% | $97.1M+22.3% | $79.3M+12.3% | $70.6M |
| Total Equity | $4.4B-46.3% | $8.3B-0.6% | $8.3B-2.1% | $8.5B-5.6% | $9.0B+1105.0% | $746.5M+153.9% | $294.0M+16.0% | $253.4M+67.7% | $151.2M+30.6% | $115.8M-4.8% | $121.7M-3.9% | $126.6M-1.6% | $128.7M+9.3% | $117.7M-9.4% | $129.9M |
SVA Balance Sheet by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q4'2520-F | Q4'2420-F | Q4'2320-F | Q4'2220-F | Q4'2120-F | Q4'2010-K | Q4'1910-K | Q4'1810-K | Q4'1710-K | Q4'1610-K | Q4'1510-K | Q4'1410-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $8.5B-30.8% | $12.3B-9.4% | $13.6B-3.0% | $14.0B-16.3% | $16.8B+781.4% | $1.9B+320.4% | $452.3M+22.3% | $369.8M+23.6% | $299.2M+41.6% | $211.4M+4.2% | $202.9M-14.9% | $238.5M-0.9% |
| Total Liabilities | $4.1B+100.7% | $2.0B-61.4% | $5.3B-4.4% | $5.5B-28.6% | $7.8B+893.8% | $781.2M+680.4% | $100.1M+28.6% | $77.9M-36.2% | $122.1M+49.4% | $81.7M+23.0% | $66.4M-31.4% | $96.8M-0.3% |
| Total Equity | $4.4B-46.3% | $8.3B-0.6% | $8.3B-2.1% | $8.5B-5.6% | $9.0B+1105.0% | $746.5M+153.9% | $294.0M+16.0% | $253.4M+67.7% | $151.2M+30.6% | $115.8M-4.8% | $121.7M-3.9% | $126.6M-1.6% |
What total assets means
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.
More Sinovac Biotech, Ltd financials
Frequently Asked Questions
What was Sinovac Biotech, Ltd's total assets in fiscal year 2025?
Sinovac Biotech, Ltd closed fiscal year 2025 with $8.5B in total assets, $4.1B in total liabilities and $4.4B in shareholder equity.
How fast is Sinovac Biotech, Ltd's total assets growing?
Sinovac Biotech, Ltd (SVA) total assets fell by 30.8% year over year, from $12.3B to $8.5B in fiscal year 2025.
How has Sinovac Biotech, Ltd's total assets changed over the years?
Across the 15 fiscal years this page covers, Sinovac Biotech, Ltd (SVA) total assets went from $215.9M in fiscal year 2011 to $8.5B in fiscal year 2025.
What was Sinovac Biotech, Ltd's total assets in the most recent quarter?
Sinovac Biotech, Ltd (SVA) reported $8.5B in total assets in Q4 2025. This represents a decrease of 30.8% from the same quarter a year earlier.
What does total assets mean on a financial statement?
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what Sinovac Biotech, Ltd (SVA) reported on that line in every period on record.